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Gastroenteropancreatic neuroendocrine neoplasms have substantially increased over the last decades.
Because of the indolent clinical course of the disease even in advance stages and the rise in the inciden-
tal diagnosis of small asymptomatic lesions, the prevalence of gastroenteropancreatic neuroendocrine
neoplasms is higher than that of pancreatic, gastric and oesophageal adenocarcinomas, making them the
second most prevalent cancer type of the gastrointestinal tract. This increase in the overall prevalenceeywords:
iagnosis
ndoscopic ultrasound
ndoscopy
astroenteropancreatic neuroendocrine
of gastroenteropancreatic neuroendocrine neoplasms has been paralleled by a growth in the importance
of the endoscopist in the care of these patients, who usually require a multidisciplinary approach. In this
manuscript the diagnostic and therapeutic role of endoscopic for gastroenteropancreatic neuroendocrine
neoplasms will be reviewed.
Gasteoplasms
herapy
© 2013 Editrice
. Introduction
The incidence of gastroenteropancreatic neuroendocrine neo-
lasms (GEP-NENs) has substantially increased over the last
ecades [1,2]. However they are still considered rare neoplasms.
he most common primary sites for GEP-NENs are the stomach
nd the small intestine, but pancreatic and rectal NENs are often
he most aggressive and challenging forms [3,4].
The clinical course of the disease is almost indolent, since
lthough up to two-thirds of patients with GEP-NENs present
ith distant metastases at the time of diagnosis, the 5-years
urvival exceeds 60% [4]. For this reason, the prevalence of GEP-
ENs is higher than that of pancreatic, gastric and oesophageal
denocarcinomas, making them the second most prevalent can-
er type of the gastrointestinal (GI) tract [5]. Furthermore, the
ide-spread use of both endoscopic diagnostic procedures and
adiological imaging modalities has exponentially increased the
ncidental discover of asymptomatic, usually small lesions [6,7].
hese lesions pose different dilemma to the clinicians taking care of
EP-NENs.
∗ Corresponding author at: Digestive Endoscopy Unit, Università Cattolica del
acro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy. Tel.: +39 0635511515;
ax: +39 0630156581.
E-mail address: albertolarghi@yahoo.it (A. Larghi).
590-8658/$36.00 © 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier
ttp://dx.doi.org/10.1016/j.dld.2013.04.007roenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
GEP-NENs are heterogeneous neoplasms and their prognosis is
strictly dependent on several factors: the primary site, with pan-
creatic tumours presenting aworse prognosis as compared to those
originating from the stomach or small intestine; the histological
classiﬁcation, as assessed by the speciﬁc WHO classiﬁcation, which
mainly depends on their proliferative activity and, ﬁnally, the stage,
as evaluated by imaging, and classiﬁed in a speciﬁc TNM system
(TNM ENETs) [8].
In this scenario, the correct localization of the primary tumour
site in metastatic disease as well as the correct staging of inciden-
tally discovered lesions are of paramount importance. A correct
histological diagnosis including the grading has also important
prognostic implications. The knowledge of all of these parameters
allows estimation of the risk of progression and death, and the risk
of recurrence after attempted curative resections [9–11].
In the last decade, the development of new and more sophisti-
cated diagnostic and therapeutic endoscopic instruments and tools
have enriched the armamentarium available to the endoscopist,
the importance of whom in the care of patients with GEP-NENs has
consequently grown. GEP-NENs, however, still represent a clinical
challenge to the endoscopist because of their small size, whichmay
render their search very difﬁcult, if not sometime impossible.
The diagnostic and therapeutic role of endoscopy in the care of
patients with GEP-NENs can be divided into several paragraphs.
Each of these paragraphs will be separately reviewed in this paper,
highlighting the current role of the endoscopic techniques and
areas where further research is recommended.
Ltd. All rights reserved.
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. Localization of the primary tumour site in metastatic
isease
Most GEP-NENs, especially those arising from the pancreas and
he small intestine, are metastatic at the time of the diagnosis
12]. In about 10% of patients after the discovery of liver or lymph
ode metastases, the primary site following a standard diagnostic
ork up with cross-sectional imaging studies such as whole body
omputed tomography (CT) scan can remain undisclosed, thus con-
guring the clinical picture of a neoplasm of unknown primary. In
his setting, a biopsy of the metastatic site would not only diagnose
ENs, but alsoprovide additional information thatmay indicate the
ost probable location of the primary lesion. A positive immuno-
istochemistry for CDX2 would indeed suggest an origin from the
I tract, staining for thyroid transcription factor-1 (TTF1) a lung
rimary, while a positive pancreatic duodenal homeobox 1 (PDX-
) or pancreatic polypeptide (PP) staining would point out towards
primary pancreatic neoplasm [8,12,13].
In the work up of patients with metastatic NENs of unknown
rimary (MNENs-UP), both oesophagogastroduodenoscopy (EGD)
nd colonoscopy should be performed, regardless of the results
f immunohistochemical studies. Duodenoscopy should also
e performed in case of negative EGD to take a better look of
he papilla’s area, while ileoscopy should always be part of the
olonoscopic examination to explore the terminal ileum. In a
etrospective analysis of 123 patients with MNENs-UP, Wang et al.
14] found that EGD was able to diagnose a primary gastric lesion
n 100% of cases, while colonoscopy was effective in diagnosing
primary colorectal lesion in about 86% of cases. Colonoscopy
lso identiﬁed a small quote of lesions located in the terminal
leum. Importantly, in this study most of the lesions that were
ventually found intraoperatively were located in the small
ntestine [14]. The small intestine is indeed the most frequent
rimary site in patients with a MNENs-UP and should be actively
nvestigated. Non-invasive techniques in this setting include both
uclear medicine techniques such as Octreoscan or more recently
68)Ga-DOTA-NOC receptor positron emission tomography/CT
PET/CT), and CT enteroclysis [15,16]. Endoscopic techniques such
s videocapsule endoscopy (VCE) and enteroscopy that are capable
f exploring the small intestine are very attractive options in
hese patients. A case of small intestine NENs detected with VCE is
hown in Fig. 1. The accuracy of VCE, however, has been reported
n only few case series with a limited number of patients [17–19].
an Tuyl et al. [17] investigated the ability of VCE to localize an
ccult intestinal primary lesion in 20 consecutive patients with
NENs-UP. VCE revealed a small-intestinal tumour in 9 patients,
ith some other abnormalities such as external compression or
rosions found in 3 additional patients [17]. However, not all
atients underwent surgery, preventing the actual accuracy of the
echnique to be determined. Johanssen and colleagues compared
Fig. 1. An example of small intestine neuroendocrine nr Disease 46 (2014) 9–17
the accuracy of VCE and computed tomography enteroclysis (CTE)
in 8 patients with MNENs-UP, with surgery as the gold standard
[18]. CTE detected the primary neoplasm in 50% of the patients
as compared to 37.5% for VCE, and also provided additional
information on extra-luminal disease, which is an important issue
in small intestine NENs [18]. The better performance of CTE as
compared with VCE has been recently conﬁrmed in a larger series
of 41 patients, where the sensitivity of CTE and VCE were 92%
and 29%, respectively (p=0.004) [19]. Furthermore, as NENs of the
small intestine often cause signiﬁcant strictures due to mesenteric
involvement with ﬁbrosis development, the use of VCE should
also be preceded by another imaging study to rule out stenosis
because of the risk for capsule retention. Indeed, a few cases of
capsule retention due to small intestine NENs have been reported
[20,21]. Differently, the data on the usefulness of enteroscopy per-
formed with double or single balloon are scanty, thus suggesting
a relatively low diagnostic yield of this procedure in the search for
primary neoplasm in patients with MNENs-UP [22].
3. GEP-NENs of the GI wall
Gastric, duodenal, and rectal NENs of the wall of the GI tract are
diagnosed with increased frequency, mostly incidentally, because
of the widespread use of diagnostic upper and lower endoscopic
examinations [23]. Recent epidemiological studies indicate that
gastric NENs are the most common form of GEP-NENs [2]. Sim-
ilarly, rectal NENs are very frequent [1,2], while duodenal NENs
are more rare accounting for only 1–2% of all GEP-NENs and are
usually associated with speciﬁc genetic syndromes, such as gas-
trinomas in multiple endocrine neoplasia type 1 (MEN-1) or Von
Recklinghausen’s disease, and can be functioning (somatostati-
noma, gastrinoma) or non-functioning.
Tumour size, degree of inﬁltration of or layer of origin within
the GI wall, and presence or absence of metastatic loco-regional
lymph nodes are very important parameters that inﬂuence treat-
ment strategy and are best assessed by endoscopic ultrasound
(EUS).
3.1. Gastric NENs
Type 1 and 2 gastric NENs, accounting for about 70–85% of
cases of gastric NENs, develop in the gastric fundus and body as
a consequence of chronic hypergastrinemia and are usually small
(<10mm) andmultiple. In about 90% of cases they are limited to the
mucosa/submucosa, while inﬁltration of the muscolaris propria is
usually observed only when their size is greater than 10–20mm
[24,25]. Lymph node metastases are found in 2–9% of type 1 and
in 10–30% of type 2 lesions and usually occur with tumours that
are greater than 20mm, inﬁltrating the muscolaris propria and/or
becoming angioinvasive [26–28]. Type 3 gastric NENs are sporadic
eoplasm detected with videocapsule endoscopy.
F. Attili et al. / Digestive and Liver Disease 46 (2014) 9–17 11
Fig. 2. Endoscopic submucosal dissection of a gastric cardia neuroendocrine neoplasm. Endoscopic view of the gastric cardia neuroendocrine neoplasm (A). After the gastric
lumen was ﬁlled with water, EUS examination showed a 7mm×6.3mm hypoechoic lesion conﬁned to the submucosal layer (B). The lesion was then marked all around
using the tip of a water jet assisted knife (C). Complete dissection of the previously marked area was achieved showing the underlying submucosa that appears blue because
of the previous injection of indigo carmine (D). Large ESD defect after complete en bloc resection of the lesion (E). Macroscopic image of the one section of the resected
specimen with margins inked (F). Neuroendocrine neoplasia with typical trabecular structure inﬁltrating the submucosa and extensive immunohistochemical expression of
chromogranin A (G). Ki-67 determination deemed to be 2%, which is indicative of low grade neuroendocrine tumour NET G1 (H). H&E (F); immunoperoxidase (G and H).
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n
a
s
N
a
m
2
e
a
a
m
n
h
e
N
g
w
l
i
f
w
3
2
t
H
e
[
a
i
i
e
s
t
d
a
f
i
3
c
h
a
b
l
i
o
s
a
m
F
c
a
l
r
c
t
f
t
d
e
p
n2 F. Attili et al. / Digestive an
eoplasms, not associated with hypergastrinemia [29], that appear
s a solitary polypoid lesion that can be found in any part of the
tomach. At the time of diagnosis, more than 70% of type 3 gastric
ENs are larger than 10mm, inﬁltrate the muscolaris propria,
nd/or are angioinvasive, thus accounting for the high rate of
etastases found at presentation (75%) [30]. For small type 1 and
tumours conﬁned to the mucosal layer after EUS examination,
ndoscopic mucosal resection (EMR) is the treatment of choice
llowing removal of the tumour en bloc and complete histological
ssessment [26]. Conversely, for bigger lesions conﬁned to the
ucosa or for those inﬁltrating the submucosa without lymph
odes involvementatEUS, endoscopic submucosaldissection (ESD)
as been proposed as the treatment of choice (Fig. 2) [31,32]. How-
ver, only a study has evaluated the effectiveness of ESD for gastric
ENs and proved this method to be effective [33]. Twenty-four
astric lesions with submucosa inﬁltration as determined by EUS
ere successfully removed en bloc. R0 resectionwas obtained in all
esions that being foundG1 or G2 tumourswith no lymphovascular
nvasion, therefore any further treatment was required. After a
ollow up of two years, no lymph node or distal organ metastases
ere found and all patients were alive. Of note, 8 lesions were type
gastric NENs that are usually more aggressive than types 1 and
and are treated similarly to gastric adenocarcinomas (partial or
otal gastrectomy with lymph node dissection and chemotherapy).
owever, for those lesions that are small (<10mm) and well differ-
ntiated (G1), conservative endoscopic treatmentmay be an option
31]. For type 3 gastric NENs, EUS may play an additional role by
ssessing the presence of regional lymph-node involvement, even
n the presence of a small lesion, and eventually allows for cytolog-
cal conﬁrmation by ﬁne-needle aspiration [30]. In these patients,
ndoscopic treatment is not an option and they should be sent for
urgical intervention. Finally, type 1 gastric NENs have a tendency
o recur; thus endoscopic surveillance every 1 or 2 years for early
etection is recommended. Biopsy of any visible lesion/polyp and
complete gastric map with multiple random biopsies in the
undus (at least 4 samples) and the antrum (at least two samples)
n addition to any visible lesion/polyps should be performed.
.2. Duodenal and rectal NENs
Duodenal and rectal NENs are usually localized in the submu-
osal layer (third layer) and characteristically appear as rounded,
ypoechoic, well demarcated small lesion with a salt and pepper
ppearance at EUS examination.
Most of the duodenal NENs are small (<10mm) and can
e treated with EMR [34], after EUS examination has excluded
oco-regional lymph node metastases [33]. Surgical resection is
ndicated for larger tumours, which are associated with a high rate
f lymph node metastases, as well as for ampullary NENs. Endo-
copic ampullectomy may represent an option in case of small
mpullary NENs without local angio-invasion and lymph node
etastases and with a EUS-guided ﬁne needle aspiration (EUS-
NA) showing high differentiation, especially in high risk surgical
andidate [35].
Similar to duodenal NENs, most rectal NENs are ≤10mm, thus
llowing safe endoscopic removal [36]. In clinical practice, most
esions present as incidental polyps that only after completely
emoved by snare polypectomy are disclosed to be NENs. In such
ases the status of the resection margins and the grading of the
umours will indicate the need for additional investigations and
or follow-up, but a complete colonoscopy is usually advocated
o exclude synchronous lesions [37]. The presence of mucosal
epression or ulceration suggests an invasive behaviour and
ndoscopic removal should thus be avoided in such cases. When
lanning the removal of large lesions (within 20mm), there is the
eed to exclude an aggressive behaviour by histology with Ki-67Fig. 3. Radial EUS image of a 2.5mm gastrinoma of the second duodenal portion.
The lesion appears hypoechoic and conﬁned to the third wall layer corresponding
to the submucosa.
evaluation, and to rule out invasion of the muscularis propria.
Tumours exceeding 20mm, with muscolaris propria invasion or
aggressive histological features should undergo surgery. In this set-
ting, EUS plays a critical role, as it is capable of accurately assessing
depth of invasion and the presence or absence of pararectal lymph
node metastases. For this reason, the ENET guidelines algorithm
for rectal NENs is based on EUS ﬁndings [37]. In a recent study
investigating more than 160 patients with rectal carcinoid, the
rate of pathologically complete resection obtained by standard
polipectomy has been shown to be only 31%, as compared to the
72% obtained with EMR or ESD [38]. In this setting, the combined
use of EUS and ESD has been shown to be safe and effective to
treat rectal carcinoids, and should be taken into consideration,
especially for lesions larger than 10mm in diameter [39].
4. Gastrinoma detection
Gastrinomas are rare GEP-NENs that secrete gastrin and cause
a clinical syndrome known as Zollinger–Ellison syndrome (ZES),
which is characterized by gastric acid hypersecretion resulting in
severe acid-related peptic disease and diarrhoea [40]. In more than
70% of the cases these tumours are located in the duodenum (most
frequently in theﬁrst andsecondduodenalportion),while a smaller
part is localized in the pancreas [41]. About 60–90% of gastrinomas
are malignant [42,43]; thus localization of the primary tumour is
essential to assess whether surgical resection is indicated, to deter-
mine the extent of the disease and whether metastatic disease to
the liver or distant sites are present and, ﬁnally, to assess changes
in tumour extent with treatments.
This task, however, can be extremely difﬁcult especially for duo-
denal lesions that in most cases have a diameter less than 1 cm
(Fig. 3), while the vast majority of pancreatic gastrinomas have a
larger diameter (mean diameter 3.8 cm) and only 6% of cases have
a diameter less than 1 cm [40]. The performance of EUS reﬂects this
different behaviour of the pancreatic and duodenal lesions, being
extremely good for detection of pancreatic gastrinomas with an
overall sensitivity of about 90%, and not sufﬁcient for duodenal
lesions with a sensitivity that drops to less than 50% [44]. Based on
these performance results, the utility of EUS for gastrinoma detec-
tion outside the pancreas has been questioned and its use remains
controversial [40]. However, as the accuracy of other imaging
modalities including CT, magnetic resonance imaging (MRI), and
nuclear medicine investigations such as Octreoscan and (68)Ga-
DOTA-NOC receptor PET/CT is also limited [45,46], EUS remains
part of a diagnostic armamentarium available to try to localize gas-
trinomas [33]. In case of failure, intraoperative transillumination of
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he duodenum is frequently used to help identifying the site for the
uodenotomy, with a sensitivity of about 83% [47].
. Pancreatic neuroendocrine neoplasms
The intragastric and intraduodenal position of the EUS probe
n close proximity to the pancreas allows the obtainment of high-
esolution images and the visualization of local anatomic details
ot detected by other imaging techniques. This peculiarity, coupled
ith the ability to perform EUS-FNA to acquire tissue samples [48],
as rapidly made EUS one of the most important and accurate tool
or theevaluationofpancreaticneurondocrineneoplasms (p-NENs)
49]. At EUS examination, p-NENs typically appear aswell rounded,
ypoechoic lesionswith a homogeneous pattern andwith clear and
egularmargins (Fig. 4). Inmore advanced cases, however, all these
eatures are lost and p-NENs may present as irregular pancreatic
ypoechoic masses that are completely indistinguishable from the
ost common pancreatic adenocarcinomas.
Pancreatic NENs are rare, but their incidence has signiﬁcantly
ncreased in the last decades. Although they represent about 1% of
ll pancreatic neoplasms, their prevalence is around 10%, mostly
ccounting for low to intermediate grade NENs with a relatively
indolent” clinical course [1,50]. Pancreatic NENs are classiﬁed as
unctional or non-functional depending on the presence or absence
f a clinical hormonal hypersecretion syndrome [51]. The func-
ional status of these neoplasms changes substantially the reason
hy and the questions that need to be answered by EUS examina-
ion. Localization of functional p-NENs, mainly insulinomas, before
urgery (see the previous chapter for gastrinoma), is the most
mportant indication to perform EUS in these patients. However,
ecause of their small diameter that in about 50% of the cases is
ess than 1 cm [52], these neoplasms can be very difﬁcult to detect.
or this task, EUS appears the most sensitive imaging modality
ith a sensitivity ranging from 57% to 94% [53–60]. Because of this
igh sensitivity, EUS has been considered in the recently published
NETS consensus guidelines as the imaging study of choice to be
erformed after other non-invasive imaging studies are negative
61]. The superiority of EUS over CT is clear and remarkable in the
tudies published up to 2000 and probably reﬂects the use of old
eneration CT scan. A study in 2003 by Gouya et al. has pointed
ut for the ﬁrst time that this difference in performance could be
vercome by the use of more sophisticated CT [60]. In their study
nvolving 30 patients with 32 insulinomas, detection of tumours
ith the use of a dual-phase thin-section multidetector CT (MDCT)
eached a sensitivity of 94%, which was absolutely comparable
o the one obtained by EUS [60]. More recently, in an attempt to
ig. 4. EUS image of a small 13mm×14mm of a well rounded, hypoechoic lesion
ith regularmargin in theheadof thepancreashighly suggestive forNENs. Thediag-
osis was conﬁrmed after examination of the core biopsy tissue specimen gathered
sing the EUS-guide ﬁne needle tissue acquisition technique.r Disease 46 (2014) 9–17 13
better clarify the role of EUS for detection of p-NENs in institutions
that use MDCT for pancreatic imaging, the John Hopkins’s group
have reviewed its experience over a 25 years period [62]. In the 56
patients with 60 p-NENs who had both CT and EUS and who under-
went surgical resection of their tumour(s), the overall sensitivity of
EUS for p-NENs detection was signiﬁcantly greater than that of CT
(91.7% versus 63.3%, p<0.001). Relevantly, this better performance
was related to the signiﬁcant higher detection rate of insulinomas
(84.2% versus 31.6%, p=0.001), which represented 76% of all func-
tional p-NENs of the evaluated cohort. Moreover, when taking into
account only those patientswho underwent 64-sliceMDCT, a trend
very close to a signiﬁcant difference in favour of EUS versus CT was
also found [93% (95% CI, 83–100%) versus 74% (95% CI, 58–91%),
p=0.06] [62]. An equal trend of EUSdetection of p-NENs overMDTC
has been found in another study involving a smaller number of
patients [63]. These results highlight that the real advantage of EUS
over MDCT is related to its potential to detect small functioning
insulinomas, which often are still missed by the latest generation
of MDCT. Moreover, the capability of localizing small functional
p-NENs can be further enhanced by the use of contrast-enhanced
harmonic EUS [64,65], which can also have a prognostic value
helping thedistinctionbetweenbenignandmalignantp-NENs [65].
Another important information that can be determined in
patients with functional p-NENs by EUS is the distance between
the lesion and the main pancreatic duct, a factor that can drive
the decision of which surgical approach to utilize (i.e. enucleation
versus resection) [61]. Finally, even though usually not required,
in same cases such as the presence of multiple lesions in different
sites and with different EUS patterns or the presence of lesions that
can mimic p-NENs like accessory spleen in patients with symp-
toms suggestive of functional p-NENs, a deﬁnitive diagnosis with
EUS-FNA may be required [66].
Differently from functional p-NENs, non-functional p-NENs are
classically discovered because of the development of symptoms
due to tumour compression or invasion of adjacent organs, orwhen
they metastasize. Moreover, possibly due to the wide spread use
of cross-sectional radiological imaging studies, non-functioning
p-NENs are now most frequently detected incidentally when
completely asymptomatic [67]. The suspicious of non-functioning
p-NENs is raised because of ﬁndings of hypervascular lesions at
CT and/or MRI and even more when the lesion is found to express
somatostatin receptors at the somatostatin-receptor scintigraphy
(SRS) or at [68] Ga-DOTATOC PET [60,68,69].
In the evaluation of patients with non-functioning p-NENs, EUS
has a manifold role. First of all, EUS-FNA should be performed to
conﬁrm that the lesion is, indeed, a non-functioning p-NEN. Recent
studies on a meaningful number of patients have reported a very
high sensitivity of EUS-FNA for the diagnosis of these neoplasms,
ranging from 87% to 90% [70–72]. This high sensitivity coupled
with the very low rate of complication reported for sampling solid
lesions including p-NENs [73], make EUS-FNA the procedure of
choice to reach the deﬁnitive diagnosis. Importantly, not only can
EUS-FNA conﬁrm the neuroendocrine nature of the pancreatic
lesion, but can also give prognostic information by predicting the
5 year survival of these patients [74] and by assessing the grad-
ing of the neoplasia by determining the Ki-67 proliferation index
[70,75–77]. Pre-operative knowledge of tumour differentiation
may be crucial for management decision for non-functioning p-
NENs. For small tumours less than2 cm indiameter,whereno study
has demonstrated a survival beneﬁt of surgery [78], and the risk of
malignancy is low [79], the choice between surgerywith the associ-
ated morbidity and mortality, and clinical follow up with the possi-
bility of leaving an aggressive tumour in place, strongly depends on
the tumour site and the value of Ki-67 proliferation index. In this
scenario, in the era of personalized medicine [80], pre-operative
Ki-67 determination may prove fundamental for the discussion
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ith a patient regarding the available therapeutic options. Simi-
arly, in patients with unresectable tumours, the choice of the most
ppropriate ﬁrst-line therapeutic regimen is critically based on the
egreeof cell proliferation indexandmay includedifferent somato-
tatin analogues, targeted therapies (i.e. everolimus and sunitinib),
eptide receptors targeted therapy, and different chemothera-
eutic schedules [81–83]. Up to recently, only few studies have
eported the use of EUS-FNA cytological specimens for Ki-67
ig. 5. Examples of grading for neuroendocrine neoplasms in EUS-ﬁne needle tissue ac
ntense immunoreactivity for chromogranin A (B) and synaptophysin (C) and rare cells wi
oderate cell atypia (E), intense immunoreactivity for chromogranin A (F) and synapto
-NEC fragmented sample showing abundant desmoplasia and solid islets of cells with
hromogranin A (J), intense and diffuse immunoreactivity for synaptophysin (K) and diff
nd J–L) immunoperoxidase.r Disease 46 (2014) 9–17
measurement showing promising results [70,75–77]. In the largest
and best designed prospective study published to date (including
both functioningandnon-functioningp-NETs),Ki-67measurement
was successful in 18 (75%) of the 24 patients evaluated [75]. All
patients underwent surgery and there was 89% agreement in Ki-
67 determination between cytological and histological samples
by the ENETS grading system criteria [84]. Despite these results,
Ki-67 expression on cytological specimens has still not gained
quisition samples. Grade 1 p-NET showing trabecular histology, mild atypia (A),
th nuclear labelling for Ki-67 (D). Grade 2 p-NET showing large trabecular structure,
physin (G) and discrete cells with nuclear labelling for Ki-67 (H). High grade, G3,
severe atypia and scarce cytoplasm (I), focal and often faint immunoreactivity for
use nuclear labelling for Ki-67 (L). (A, E, and I) Haematoxylin and eosin; (B–D, F–H
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idespread use due to the difﬁculty to obtain reproducible results
nd the availability of tissue biopsy specimens has been advocated
78].
To overcome these limitations of cytological Ki-67 determina-
ion, our groups have used a recently developed technique that we
efer as to EUS-guided ﬁne needle tissue acquisition (EUS-FNTA)
o distinguish it from EUS-FNA [85], to gathered sample for his-
ological examination in patients with suspicious non-functioning
-NENs [86]. Thirty patients with a mean diameter of the lesions of
6.9±6.1mm were enrolled. The procedure, which is performed
sing a 19-gauge EUS needle, was technically successful in all
atients without complications. In 28 of them, tissue samples for
istological examination were obtained and the diagnosis of non-
unctioning p-NENs conﬁrmed (Fig. 5). Of note, tissue sampleswere
lso successfully obtained from lesions in the head of the pancreas
nd uncinate process, two sites that require the trans-duodenal
pproach, a known limitation of the large gauge biopsy EUS nee-
les [87,88]. In 26of the 28patientswith available tissue specimens
92.9% and 86.6% of the initial entire cohort), we were able to also
erformKi-67determination (Fig. 5). In12patientswhounderwent
urgery we could compare Ki-67 expression on EUS-FNTA sam-
les and the surgical specimens that represent the reference gold
tandard. Using a cut-off of 2% to distinguish G1 from G2 tumours,
oncordance between pre- and post-surgical Ki-67 determination
as found in 83.3% of the patients. Interestingly, when a cut-off of
% that several strands of evidence suggest thatmay bemore useful
han the 2% value to deﬁne G2 tumourswas applied [89,9], the con-
ordance was found in all cases [86]. These very promising results
eed to be reproduced by other groups before this procedure can
ecome the standard of care to evaluate these patients.
Another emerging application of EUS for both functioning and
on-functioning p-NENs is the performance of EUS-guided ﬁne
eedle tattooing (EUS-FNT) of the lesion to facilitate its precise
ocalizationduring surgery. Pre-operative tattoo canbevery impor-
antwhen laparoscopic surgery isperformed, becauseof the limited
bility of the surgeon to clearly identify and palpate small pancre-
tic lesions, which can lead to conversion to an open procedure in
s high as 30%of cases [90]. After the publication of few case reports
hat demonstrated the lack of complications [91–94], the JohnHop-
ins’ group reported the ﬁrst case series involving 13 patients (6 of
hom had p-NENs) who underwent EUS-FNT to facilitate recogni-
ion of the lesion during laparoscopic distal pancreatectomy [95].
he tattoo was done by injecting 1–5ml of sterile puriﬁed carbon
articles (GI Spot; GI Supply, Camp Hill, PA), 3–5mm into the pan-
reatic parenchyma to the patient’s right of the lesion (towards
he pancreatic head). The procedure was feasible in all cases, with-
ut complications and all lesionswere easily recognized at surgery.
he same group clearly showed that the increased recognition of
he pancreatic lesion during resection was associated with a sig-
iﬁcant decrease in the operative time as compared with patients
ho undergo the same surgical procedure without a tattoo [96].
his has led in their institution to the routine use of EUS-FNT when
mall pancreatic lesions are resected laparoscopically.
Finally, p-NENs can become a target for EUS-guided tumour
blation therapies that are under development and represent the
atural evolution of EUS from a diagnostic into a more thera-
eutic/interventional [97,98]. Three cases of EUS-guided alcohol
blation of symptomatic functioning p-NENs in high-risk surgical
atients have been reported in the literature [99–101]. In all cases,
blation led to long-term symptoms resolution. However, in one
atient with MEN I and two Vipomas, the second tumour ablation
as complicated by formation of a small pancreatic necrotic lesionecondary to minimal effusion of ethanol during needle retrac-
ion,whichwas treatedwith laparoscopic necrosectomy [101]. This
nderlying the difﬁculty of treating small p-NENs that are sur-
oundedbynormal pancreatic tissue that if involvedby the ablationr Disease 46 (2014) 9–17 15
treatment can lead to dangerous complications. Moreover, alcohol
may not represent the best treatment because of the possibility of
distant complication such as portal vein thrombosis that has been
described after alcohol ablation of pancreatic cysts [102]. However,
the possibility of minimally invasive treatment of small p-NENs by
EUS remains attractive and future research will better clarify the
potential role for this procedure.
6. Conclusions
In conclusion, endoscopic procedures have a pivotal role in the
diagnostic work-up and in the therapy of GEP-NENs.
Upper and lower standard GI endoscopy should represent the
ﬁrst step in patients with MNENs of unknown primary, followed
by an intense investigation of the small intestine, since this latter is
the most frequent primary site. VCE has showed suboptimal diag-
nostic accuracy and should be proposed only after the exclusion
of strictures, since cases of retention have been described. Stud-
ies on the role of enteroscopy in patients with MNENs of unknown
primary origin are still scanty to draw any ﬁrm conclusion.
EUS has a crucial role in the setting of GEP-NENs of the GI wall,
since it provides information on size, deep of invasion and loco-
regional metastasis. EUS-guided FNA can also provide a deﬁnite
diagnosis and useful information (i.e. Ki-67 evaluation) for the cor-
rect management of this type of lesions. Furthermore, EUS can
correctly select ideal candidates for endoscopic resection (EMR and
ESD).
EUS has a decisive role in the setting of pancreatic neuroen-
docrine neoplasms. It can help to correctly localize the tumour
when other non-invasive procedures have failed and can provide
useful additional information (i.e. distance from the pancreatic
duct, Ki-67 proliferation index) for the best therapeutic manage-
ment (surgery, conservative approach, type of anti-tumour therapy
in case of unresectable tumours). Furthermore, the possibility of
EUS-guided FNA tattooing of pancreatic lesions may help sur-
geons to ﬁnd the neoplasm and avoid demolitive surgery. Finally,
EUS-guided therapies (i.e. alcohol ablation), especially in patients
unsuitable for surgery, are under investigation and will deﬁnitively
represent the future ﬁeld of interest.
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